Study shows absence of omicron neutralization with the Pfizer and AstraZeneca shots

New research from the University of Oxford, Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum, showed that Pfizer and AstraZeneca vaccination antibodies are ineffective against the omicron variant. It is available as a preprint from medRxiv.

They studied serum among people given the Pfizer BNT162b2 shot (n=21) and the AstraZeneca AZD1222 jab (n=22). The sera were obtained 28 days after the second dose of the vaccinations. 

Both vaccine groups did not develop COVID-19 before.

Methodology

The study assesses the neutralizing ability of the antibodies against several variants—the Victoria, Beta, Delta, and omicron. Victoria is an early variant in the pandemic.

Results and Conclusion

There was a substantial fall in neutralisation titres in recipients of both AZD1222 (n=22) and BNT16b2 (n=21) primary courses,
with evidence of some recipients failing to neutralise at all.

This will likely lead to increased breakthrough infections in previously infected or double vaccinated individuals, which could drive a further wave of infection, although there is currently no evidence of increased potential to cause severe disease, hospitalization or death.

The figure below shows the neutralization ability of the sera from the Pfizer and AstraZeneca vaccinees among the four variants.

Note the decline and absence of neutralizing ability against the omicron variant.

This is the first study that has tested neutralizing antibodies vaccinees against the omicron variant. They did not include antibodies from people who previously recovered from COVID-19 who may have natural immunity against omicron. That is why their conclusion that unvaccinated people are prone to omicron is debatable.

Natural immunity against COVID-19 can be protective to omicron. That’s because the SARS-CoV-2 virus mutates in the host, and immunity is generated against all of those mutations.

Addendum: On Dec 14, 2021, People who recovered from COVID-19 have effective T-cells against the omicron

• The human body is a SARS-CoV-2 variant factory, and that’s a good thing
• Harvard: Immunity from mild COVID-19 disease is much better than vaccination

Furthermore, there is no evidence that the omicron is more virulent than previous variants (the authors said so themselves), so why expose yourself to the adverse effects of the jabs?

Don’t Get Sick!

Knowledge about Covid-19 is rapidly evolving. Stay current by subscribing. Feel free to share and like.

If you find value in the articles, please consider donating to show your support.

Related:

1. Ten Studies showing a low risk of COVID-19 reinfection among unvaccinated
2. High Anti-SARS-CoV-2 Antibodies Among the Unvaccinated in Bangui, Central African Republic
3. Protective Antibodies against SARS-CoV-2 are the same in Convalescent and Vaccinated
4. Asymptomatic or mild symptomatic COVID-19 elicits effective and long-lasting antibody responses in children and adolescents
5. Can coronaviruses elicit long-lasting immunity?
6. 60% may already have Immunity to COVID-19
7. Pre-Existing T-Cells Stop COVID-19 Before it Starts
8. Harvard: Immunity from mild COVID-19 infection much better than vaccination
9. Natural Immunity Protected Tanzania and Zambia from COVID-19
10. CD4+ Cross-Reactivity between Seasonal Coronavirus Colds and COVID-19

Reference:

1. Dejnirattisai et al. Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum.
   medRxiv 2021.12.10.21267534; doi: https://doi.org/10.1101/2021.12.10.21267534

© 2018 – 2021 Asclepiades Medicine, L.L.C. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment

As an Amazon Associate, I earn from qualifying purchases.